KRAS and metastatic neoplasm: While this could be a random effect, it may also suggest that, at least in the setting of non-metastatic disease/limited tumour burden, tumours with specific KRAS mutations (i.e., G12V) are less likely to release DNA in blood compared to those harbouring different mutations (i.e., G12D).